Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Weekly.

Pharm D Corner

Insights from doctors of pharmacy.
Mimi Chen

Biosimilars are supposed to save us money, but whose money are they saving?

Recent updates to the Medicare reimbursement policies, the passage of the president’s Bipartisan Budget Act of 2018, and analyses of these changes from various consultants have unveiled the chaos that is biosimilar reimbursement.

Mimi Chen, PharmD
Amid heightened focus on prescription drug prices and slow progress from Congress, states are taking matters into their own hands. California is the prime example. Gov. Jerry Brown, a Democrat, signed SB 17 into law early last month. The law requires drug makers to report price hikes that accumulate…
Harman Kaur
Back in the 20th century, many physicians conducted home visits. Whether it was for a serious illness or a minor problem like a common cold, patients had access to doctors without leaving their homes. Today, many patients don’t have proper access to physicians at a health care facility, let alone…
Simi Mathew
With prices hitting new highs, payers are more interested than ever in seeing evidence that the drugs they pay for will perform as well as they did in clinical trials. They’re also looking at outcomes beyond narrow clinical endpoints such as blood pressure and placing emphasis on improvements in quality…
Mimi Chen, PharmD
In a time of deep partisan division, the 21st Century Cures Act stands out as an exception to the rule. The law passed late last year with broad support from both Democrats and Republicans and was signed into law by former President Obama. The Cures Act is intended to modernize and accelerate medical…
Gaurav Dhanda, PharmD
A few weeks ago, the U.S. Department of Health and Human Services made a final rule on a policy that implemented incentive payment provisions in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). This rule, which takes effect January 2017, has huge potential to change the health care…
Mimi Chen, PharmD
You’ve all seen the headlines and statistics: “Drug overdose deaths have now surpassed fatal car accidents, with more than 47,00 lethal overdoses in 2014.” “In 2012, 259 million prescriptions were written for opioids, which is more than enough to give every American adult their own bottle of…
Krishna R. Patel, PharmD
The 340B Program has evolved into a source of major profit for some covered entities. Pharmaceutical manufacturers know this, but do payers? The 340B Program is a federal program designed that requires drug manufacturers to provide outpatient drugs to certain health care organizations that serve a predominantly…